Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1327

1.

Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.

Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE; Active Bacterial Core Surveillance Team.

Clin Infect Dis. 2008 Jan 1;46(1):1-13. doi: 10.1086/524041.

PMID:
18171206
[PubMed - indexed for MEDLINE]
Free Article
2.

Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.

Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team.

Pediatrics. 2005 May;115(5):1220-32.

PMID:
15867028
[PubMed - indexed for MEDLINE]
3.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
[PubMed - indexed for MEDLINE]
4.

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ.

Vaccine. 2004 Dec 9;23(4):470-9.

PMID:
15530695
[PubMed - indexed for MEDLINE]
5.

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.

Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP.

Pediatrics. 2007 Jan;119(1):e22-9.

PMID:
17200247
[PubMed - indexed for MEDLINE]
Free Article
6.

Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.

Trotter CL, Edmunds WJ.

Med Decis Making. 2006 Jan-Feb;26(1):38-47.

PMID:
16495199
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
[PubMed - indexed for MEDLINE]
8.

Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.

Miller MA, Wenger J, Rosenstein N, Perkins B.

Pediatr Infect Dis J. 1999 Dec;18(12):1051-9.

PMID:
10608623
[PubMed - indexed for MEDLINE]
9.

Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation.

Skull SA, Butler JR, Robinson P, Carnie J.

Int J Epidemiol. 2001 Jun;30(3):571-8; discussion 578-9.

PMID:
11416085
[PubMed - indexed for MEDLINE]
Free Article
10.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

PMID:
20044845
[PubMed - indexed for MEDLINE]
Free Article
11.

Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.

De Wals P, Nguyen VH, Erickson LJ, Guay M, Drapeau J, St-Laurent J.

Vaccine. 2004 Mar 12;22(9-10):1233-40.

PMID:
15003652
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
[PubMed - indexed for MEDLINE]
13.

Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.

Caro JJ, Möller J, Getsios D, Coudeville L, El-Hadi W, Chevat C, Nguyen VH, Caro I.

BMC Public Health. 2007 Jun 29;7:130.

PMID:
17603880
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cost-effectiveness and potential impact of rotavirus vaccination in the United States.

Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI.

Pediatrics. 2007 Apr;119(4):684-97.

PMID:
17403839
[PubMed - indexed for MEDLINE]
Free Article
15.

Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.

Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ.

PLoS One. 2013 May 31;8(5):e65036. doi: 10.1371/journal.pone.0065036. Print 2013.

PMID:
23741448
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].

da Silva A, Parent du Châtelet I, Beckr Gaye A, Dompnier JP, Seck I.

Sante. 2003 Oct-Dec;13(4):215-23. French.

PMID:
15047438
[PubMed - indexed for MEDLINE]
17.

Pertussis in adolescents and adults: should we vaccinate?

Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA.

Pediatrics. 2005 Jun;115(6):1675-84.

PMID:
15930232
[PubMed - indexed for MEDLINE]
18.

Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.

Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA; Active Bacterial Core surveillance (ABCs) team.

Vaccine. 2001 Aug 14;19(31):4566-75.

PMID:
11483285
[PubMed - indexed for MEDLINE]
19.

Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.

Scott RD 2nd, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE.

Am J Prev Med. 2002 Aug;23(2):98-105.

PMID:
12121797
[PubMed - indexed for MEDLINE]
20.

Varicella vaccination in Italy : an economic evaluation of different scenarios.

Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B.

Pharmacoeconomics. 2004;22(13):839-55.

PMID:
15329030
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk